Compass Therapeutics says a treatment evaluating its cancer treatment didn’t meet the secondary endpoint for an unexpected ...

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares fell 23% to $3.85 in premarket ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus ...

The trial is testing Tovecimig in combination with Paclitaxel in patients with a rare disease affecting the bile ducts or ...

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares sank 61% to $1.96, at one point ...

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements. In the treatment of newly diagnosed biliary tract cancer, the current standard ...

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), ...

A new targeted treatment for a rare and aggressive bile duct cancer has been approved by NICE, offering patients longer ...

New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter ...

When do you have tests for bile duct cancer? Bile duct cancer is also called cholangiocarcinoma. It is a rare type of cancer that develops in the bile ducts. Most people are diagnosed with bile duct ...

People who take low-dose aspirin have a significantly lower risk of developing bile duct cancer than nonusers, new research shows. The findings add to the already substantial evidence that aspirin has ...